EXTH-45. THERAPEUTIC EFFICACY OF MUTANT ISOCITRATE DEHYDROGENASE 1 (IDH1) INHIBITOR SYC-435 WITH STANDARD THERAPY IN PATIENT-DERIVED IDH1 MUTANT GLIOMA XENOGRAFT MOUSE MODELS

Mutation in isocitrate dehydrogenase 1 (IDH1) occurs in >70% of WHO grade II/III astrocytomas, oligodendrogliomas and secondary glioblastoma. The mutant enzyme catalyzes the reduction of α-ketoglutaric acid to D-2-hydroxyglutaric acid, leading to cancer initiation. In this study, we examined ther...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Kogiso, Mari, Qi, Lin, Zhang, Huiyuan, Braun, Frank, Du, Yuchen, Huang, Lei, Guo, Lei, Huang, Yulun, Lindsay, Holly B, Zhao, Sibo, Injac, Sarah, Baxter, Patricia, Su, Jack, Perlaky, Laszlo, Parsons, Williams, Chintagumpala, Murali, Adekunle, Adesina, Wang, Jialiang, Song, Yongcheng, Li, Xiao-Nan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2019
Aiheet:
Experimental Therapeutics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847717/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.377
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia